From the first dose,
eligible commercially insured
patients pay $15 or less*
A dedicated Nurse Navigator
by your side from day 1†
An online home for
tools and information
From the moment you receive your prescription, BIMZELX Navigate is here for you—tailored patient support that's designed to be easy to use and available whenever you need it.
We know starting or switching biologics can be complicated, even after you've been prescribed by your healthcare provider.
When you enroll, you’ll be paired with a dedicated Nurse Navigator—one person you can rely on to connect you to everything BIMZELX Navigate has to offer. They’ll answer your questions, keep you up-to-date about your prescription and insurance status, and discuss your treatment goals.†
Stay focused on your treatment goals with tools and online resources.
Join BIMZELX Navigate today
UCB, the maker of BIMZELX, remains committed to helping moderate to severe plaque psoriasis patients gain access to the medicines we manufacture. The UCB Patient Assistance Program may be able to help if you do not have health insurance or if you otherwise cannot afford your medication.
The UCB Patient Assistance Program may provide medication at no cost to eligible patients who are unable to pay for their BIMZELX prescription.
Once enrolled in the UCB Patient Assistance Program you can join BIMZELX Navigate where you'll have access to patient support offerings including a Nurse Navigator, injection training, medication reminders, and more.
Get started by reviewing the program instructions and filling out the application form.
UCBCares® is the hub for information on all UCB products. Reach out to our team of nurses, pharmacists, and customer service professionals to:
Connect With Us
BIMZELX Bridge: Eligible patients must be 18 years of age or older with commercial insurance and a valid prescription consistent with FDA-approved product labeling for BIMZELX® (bimekizumab-bkzx). Eligible patients may pay as little as $15 per dose of BIMZELX for up to two years or until the patient’s commercial insurance plan approves coverage for the drug, whichever comes first. Program is not available (1) to patients whose prescriptions are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded health care programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s insurance covers the drug, (3) to uninsured or cash-paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to program rules and federal and state laws. Patients may be asked to re-verify insurance coverage status during participation in the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription. The patient, or healthcare provider on the patient’s behalf, must not submit any claim for reimbursement for product provided under this program to any third-party payer. UCB reserves the right to end or amend this program without notice.
For initial enrollment into the program, the patient must be experiencing a delay in, or have been denied, coverage for BIMZELX by their commercial insurance plan. To maintain eligibility in the program, the following are required: (1) a prior authorization request has been submitted and/or coverage remains unavailable for the patient; and (2) if the prior authorization is denied by the payer, the prescriber must submit an appeal within the first sixty (60) days of the prior authorization denial and a prior authorization must be submitted every six (6) months thereafter or documentation as may otherwise be required by the payer.
BIMZELX Savings: Eligible patients may pay $5 per dose. Available to individuals 18 years of age or older with commercial insurance coverage with a valid prescription consistent with FDA-approved product labeling for BIMZELX® (bimekizumab-bkzx). Not valid (1) for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s commercial insurance plan reimburses for the entire cost of the drug, (3) for uninsured or cash paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to program rules and federal and state laws. The value of the program is exclusively for the benefit of patients and is intended to be credited in full towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance and deductibles. Patient may not seek reimbursement for the value of this program from other parties, including third-party payers (ie, any health insurance program or plan, or public payers like Medicare, Medicaid, Medigap, TRICARE, VA, and DoD). Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the program. This program cannot be combined with any other savings, free trial, or similar offer for the specified prescription. UCB reserves the right to amend or end this program at any time without notice.
IMPORTANT SAFETY INFORMATION:
What is the most important information I should know about BIMZELX® (bimekizumab-bkzx)?
BIMZELX is a medicine that affects your immune system. BIMZELX may increase your risk of having serious side effects, including:
Indication: BIMZELX® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet light alone or with pills (phototherapy).